AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23049087 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonarteritic anterior ischemic optic neuropathy at 20 Hz
Number of subjects: 117
Study 23049087 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinitis pigmentosa at 20 Hz
Number of subjects: 117
Study 23049087 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal artery occlusion at 20 Hz
Number of subjects: 117
Study 23049087 — intervention group
Group type: COMPARATOR
Intervention: Test-retest difference in healthy group at 20 Hz
Number of subjects: 117
Study 23049087 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest difference in disease groups at 20 Hz
Number of subjects: 117
Study 19720927 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg alone
Number of subjects: 167
Study 19720927 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus irinotecan 340 mg/m2 or 125 mg/m2
Number of subjects: 167
Study 17471998 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolit
Number of subjects: 20
Study 17471998 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 20
Study 15186955 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine
Number of subjects: 40
Study 15186955 — intervention group
Group type: EXPERIMENTAL
Intervention: Gin
Number of subjects: 40
Study 12365881 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensated Work Therapy (CWT)
Number of subjects: 142
Study 12365881 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 142
Study 11345379 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold stimulation (STS) guided slow pathway (SP) ablation
Number of subjects: 100
Study 11345379 — intervention group
Group type: COMPARATOR
Intervention: Conventional criteria for SP ablation
Number of subjects: 100
Study 9000658 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 2 g
Number of subjects: 1493
Study 9000658 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 3 g
Number of subjects: 1493
Study 9000658 — intervention group
Group type: COMPARATOR
Intervention: PLA/AZA
Number of subjects: 1493
Study 9000658 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 2 g and MMF 3 g
Number of subjects: 1493
Study 8517509 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic mixture
Number of subjects: 24
Study 8517509 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 24
Study 3323512 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral catheter removal in the early morning
Number of subjects: 0
Study 3323512 — intervention group
Group type: COMPARATOR
Intervention: Urethral catheter removal in the late night
Number of subjects: 0
Study 3323512 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients presenting with acute urinary retention
Number of subjects: 0
Study 30124473 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone initiated alongside ART in selected patients with CD4 less than 100 cells/μl
Number of subjects: 0
Study 30124473 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART initiation in TB patients
Number of subjects: 0
Study 30124473 — intervention group
Group type: EXPERIMENTAL
Intervention: ART
Number of subjects: 0
Study 30124473 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0
Study 26702772 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX (capecitabine, oxaliplatin)
Number of subjects: 441
Study 26702772 — intervention group
Group type: COMPARATOR
Intervention: modified FOLFOX6 (5‐fluorouracil, leucovorin, oxaliplatin)
Number of subjects: 441
Study 26702772 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMP(+) tumors
Number of subjects: 441
Study 24152889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous bisglycinate 25 mg iron/day
Number of subjects: 80
Study 24152889 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate 50 mg iron/day
Number of subjects: 80
Study 22418243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (50mg/m(2)) on days 1, 8, 29, and 36 and etoposide (50 mg/m(2)) on days 1‐5 and 29‐33 plus 60 Gy of thoracic radiotherapy (TRT)
Number of subjects: 65
Study 22418243 — intervention group
Group type: COMPARATOR
Intervention: Weekly concurrent carboplatin (AUC = 2) and paclitaxel (45 mg/m(2)) plus 60 Gy of thoracic radiotherapy (TRT)
Number of subjects: 65
Study 22418243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/etoposide (PE) regimen
Number of subjects: 65
Study 22418243 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin (PC) regimen
Number of subjects: 65
Study 20145553 — intervention group
Group type: EXPERIMENTAL
Intervention: Video + cues
Number of subjects: 9
Study 20145553 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal-only
Number of subjects: 9
Study 20145553 — intervention group
Group type: COMPARATOR
Intervention: Video-only
Number of subjects: 9
Study 19218664 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Flex
Number of subjects: 30
Study 19218664 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 30
Study 15998425 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-interferon-based therapy (N-IFN-BT) - ribavirin (600-800 mg) + amantadine (200 mg) + ursodeoxycholic acid (UDCA) (500 mg) for 24 weeks
Number of subjects: 170
Study 15998425 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-interferon-based therapy (N-IFN-BT)
Number of subjects: 170
Study 15998425 — intervention group
Group type: COMPARATOR
Intervention: Silymarin therapy - 450 mg/day for 24 weeks
Number of subjects: 170
Study 12531669 — intervention group
Group type: EXPERIMENTAL
Intervention: lightweight removable wrist splint
Number of subjects: 66
Study 12531669 — intervention group
Group type: COMPARATOR
Intervention: plaster cast
Number of subjects: 66
Study 10386713 — intervention group
Group type: EXPERIMENTAL
Intervention: Late course accelerated hyperfractionated (LCAF) group
Number of subjects: 85
Study 10386713 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF) group
Number of subjects: 85
Study 8886216 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprelan 500 mg
Number of subjects: 129
Study 8886216 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprelan 1000 mg
Number of subjects: 129
Study 8886216 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg
Number of subjects: 129
Study 8886216 — intervention group
Group type: COMPARATOR
Intervention: Codeine 30 mg
Number of subjects: 129
Study 8886216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 8886216 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprelan (both doses)
Number of subjects: 129
Study 1878587 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 1,200 mg/d, 1,600 mg/d, and 2,000 mg/d from day -10 through day +100 posttransplant
Number of subjects: 30
Study 1878587 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 30
Study 29072852 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepitel Film
Number of subjects: 36
Study 29072852 — intervention group
Group type: COMPARATOR
Intervention: Sorbolene cream (NZ) or Biafine cream (China)
Number of subjects: 36
Study 27134249 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) monotherapy
Number of subjects: 474
Study 27134249 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (ETN) with Methotrexate (MTX)
Number of subjects: 474
Study 24373927 — intervention group
Group type: EXPERIMENTAL
Intervention: Hs-CRP (0) - freshly collected sample
Number of subjects: 30
Study 24373927 — intervention group
Group type: COMPARATOR
Intervention: Hs-CRP (LT) - samples stored at -80°C for 7-11 years
Number of subjects: 30
Study 22775078 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 4 mg
Number of subjects: 28
Study 22775078 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal aflibercept 0.15 mg
Number of subjects: 28
Study 20151792 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2) 1 mg/day + norethisterone acetate (NETA) 0.5 mg/day for 2 months, followed by placebo for 4 months
Number of subjects: 60
Study 20151792 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2) 1 mg/day + norethisterone acetate (NETA) 0.5 mg/day for 4 months, followed by placebo for 2 months
Number of subjects: 60
Study 20151792 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 60
Study 18330483 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 64
Study 18330483 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrostimulation (FES)
Number of subjects: 64
Study 18330483 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor training (PFT)
Number of subjects: 64
Study 17141704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (microfinance and training curriculum)
Number of subjects: 8
Study 17141704 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 8
Study 12697871 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 72-hour infusions of carmustine (BiCNU) and cisplatin followed by radiation therapy
Number of subjects: 219
Study 12697871 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy with standard adjuvant BiCNU
Number of subjects: 219
Study 12697871 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm (carmustine and cisplatin)
Number of subjects: 219
Study 11030166 — intervention group
Group type: EXPERIMENTAL
Intervention: Two plasma exchanges (PE)
Number of subjects: 556
Study 11030166 — intervention group
Group type: EXPERIMENTAL
Intervention: Four plasma exchanges (PE)
Number of subjects: 556
Study 9772542 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1
Number of subjects: 20
Study 9772542 — intervention group
Group type: COMPARATOR
Intervention: Control (N. S.)
Number of subjects: 20
Study 7902369 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of naltrexone
Number of subjects: 48
Study 7902369 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of naltrexone
Number of subjects: 48
Study 7902369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 2994500 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule A (once daily by rapid infusion)
Number of subjects: 55
Study 2994500 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule B (continuous 24 hr infusion)
Number of subjects: 55
Study 2994500 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule C (divided doses every eight hours by rapid infusion)
Number of subjects: 55
Study 2994500 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (STD)
Number of subjects: 55
Study 2994500 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups B + C (combined)
Number of subjects: 55
Study 2994500 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups A + STD (combined)
Number of subjects: 55
Study 31128958 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention targeting physicians (intensive 2-day training workshop, educational outreach visits, mobile health application)
Number of subjects: 357
Study 31128958 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention targeting physicians
Number of subjects: 357
Study 31128958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 357
Study 29314355 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation with oncology social workers (OSWs)
Number of subjects: 226
Study 27227568 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs) at 0.5 mT, 12 Hz, for 30 minutes
Number of subjects: 43
Study 27227568 — intervention group
Group type: COMPARATOR
Intervention: Sham PEMFs
Number of subjects: 43
Study 24497796 — intervention group
Group type: COMPARATOR
Intervention: CT-guided sclerotherapy without ethanol concentration monitoring (group A)
Number of subjects: 67
Study 24497796 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided sclerotherapy with ethanol concentration monitoring (group B)
Number of subjects: 67
Study 23364033 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive upper arm exercise for 30 minutes per session, twice a day for 2 weeks
Number of subjects: 50
Study 23364033 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 50
Study 20008966 — intervention group
Group type: EXPERIMENTAL
Intervention: Proscriptive orientation priming
Number of subjects: 0
Study 20008966 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptive orientation priming
Number of subjects: 0
Study 20008966 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgressions representing proscriptive violations
Number of subjects: 0
Study 20008966 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgressions representing prescriptive violations
Number of subjects: 0
Study 18534554 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (body weight-supported treadmill training)
Number of subjects: 30
Study 18534554 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity exercise
Number of subjects: 30
Study 18534554 — intervention group
Group type: COMPARATOR
Intervention: Zero-intensity education group
Number of subjects: 30
Study 15940046 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (LDD) infusion over the second 3-hr period
Number of subjects: 20
Study 15940046 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (LDD) infusion over both the first and third 3-hr periods
Number of subjects: 20
Study 11899820 — intervention group
Group type: EXPERIMENTAL
Intervention: Amixin
Number of subjects: 113
Study 11899820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon
Number of subjects: 113
Study 11899820 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 1a and 2a)
Number of subjects: 113
Study 10412886 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g of paracetamol orally
Number of subjects: 50
Study 8590154 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplement of 1000 IU/day vitamin D for 1 year
Number of subjects: 75
Study 8590154 — intervention group
Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 75
Study 2188314 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen, a topically applied nonsteroidal anti-inflammatory agent, preoperatively administered.
Number of subjects: 99
Study 7002479 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate (250 mg, 3 times daily for 6 to 8 weeks)
Number of subjects: 20
Study 7002479 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 capsules, 3 times daily for 6 to 8 weeks)
Number of subjects: 20
Study 30970655 — intervention group
Group type: EXPERIMENTAL
Intervention: Armeo Spring robot-assisted trainer (n = 17)
Number of subjects: 42
Study 30970655 — intervention group
Group type: COMPARATOR
Intervention: Kinect-based system (n = 25)
Number of subjects: 42
Study 28595498 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 2704
Study 28595498 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smoking
Number of subjects: 2704
Study 28595498 — intervention group
Group type: EXPERIMENTAL
Intervention: Male former smokers
Number of subjects: 2704
Study 26224692 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-directed antibiotic therapy for 2 weeks
Number of subjects: 8
Study 23839583 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with alglucosidase alfa
Number of subjects: 14
Study 23839583 — intervention group
Group type: COMPARATOR
Intervention: Control group (HMV alone)
Number of subjects: 14
Study 21647724 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week school-based back education programme (predominantly biomechanically oriented) implemented by a physical therapist
Number of subjects: 194
Study 21647724 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 194
Study 19792837 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS)
Number of subjects: 139
Study 19792837 — intervention group
Group type: COMPARATOR
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 139
Study 16888272 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 0
Study 16888272 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 14611914 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy after complete resection
Number of subjects: 0
Study 14611914 — intervention group
Group type: COMPARATOR
Intervention: Postoperative treatments (chemotherapy, radiotherapy or both)
Number of subjects: 0
Study 11074215 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation
Number of subjects: 0
Study 11074215 — intervention group
Group type: COMPARATOR
Intervention: Intra-aortic balloon pumping
Number of subjects: 0
Study 8844019 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) at doses of 50, 125, or 250 micrograms/m2 daily by subcutaneous self-injection for 28 days
Number of subjects: 12
Study 8844019 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 12
Study 1636624 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide with fish oil (8 g/d)
Number of subjects: 10
Study 1636624 — intervention group
Group type: COMPARATOR
Intervention: Glyburide alone
Number of subjects: 10
Study 1636624 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide with fish oil
Number of subjects: 10
Study 2936285 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 mg . kg‐1 atracurium dibesylate
Number of subjects: 35
Study 2936285 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg . kg‐1 atracurium dibesylate
Number of subjects: 35
Study 2936285 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20 mg . kg‐1 atracurium dibesylate
Number of subjects: 35
Study 2936285 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 mg . kg‐1 atracurium dibesylate
Number of subjects: 35
Study 31296491 — intervention group
Group type: EXPERIMENTAL
Intervention: NBTXR3 plus radiotherapy
Number of subjects: 176
Study 31296491 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 176
Study 29557754 — intervention group
Group type: EXPERIMENTAL
Intervention: AC+AN+HL ointment mixture (Group A, N=21)
Number of subjects: 41
Study 29557754 — intervention group
Group type: COMPARATOR
Intervention: AC ointment alone (Group B, N=20)
Number of subjects: 41
Study 26032635 — intervention group
Group type: EXPERIMENTAL
Intervention: AFXL pretreatment + AHES
Number of subjects: 10
Study 26032635 — intervention group
Group type: EXPERIMENTAL
Intervention: AFXL pretreatment + EMLA cream
Number of subjects: 10
Study 26032635 — intervention group
Group type: COMPARATOR
Intervention: Sham AFXL + AHES
Number of subjects: 10
Study 26032635 — intervention group
Group type: COMPARATOR
Intervention: Sham AFXL + EMLA cream
Number of subjects: 10
Study 24796381 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for limiting drinking (social reasons)
Number of subjects: 254
Study 24796381 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for limiting drinking (lifestyle reasons)
Number of subjects: 254
Study 24796381 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for limiting drinking (impairment concerns)
Number of subjects: 254
Study 22349562 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding a long baton
Number of subjects: 0
Study 22349562 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding a short baton
Number of subjects: 0
Study 22349562 — intervention group
Group type: COMPARATOR
Intervention: No baton
Number of subjects: 0
Study 19837180 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 46
Study 19837180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 17589284 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based collaborative peer advisor/advanced practice nurse intervention
Number of subjects: 247
Study 17589284 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 247
Study 15960427 — intervention group
Group type: EXPERIMENTAL
Intervention: PMBL (Polivalent Mechanical Bacterial Lysate) - 1 tablet a day for the first ten days during three consecutive months.
Number of subjects: 114
Study 15960427 — intervention group
Group type: EXPERIMENTAL
Intervention: CLBL (oral immunostimulating lysate) - 1 capsule a day for the first ten days during three consecutive months.
Number of subjects: 114
Study 15960427 — intervention group
Group type: COMPARATOR
Intervention: Control NT - no immunostimulating treatment.
Number of subjects: 114
Study 12010356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV) 100-400 mg
Number of subjects: 97
Study 12010356 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV) 400-1800 mg
Number of subjects: 97
Study 10515817 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccines (3 experimental vaccines containing 6B and 19F)
Number of subjects: 0
Study 10515817 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccines (2 experimental vaccines)
Number of subjects: 0
Study 10515817 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccines (1 experimental vaccine)
Number of subjects: 0
Study 10515817 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between opsonophagocytic titers and IgG antibody levels by ELISA
Number of subjects: 0
Study 7743989 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ORS (100 ml/kg)
Number of subjects: 150
Study 7743989 — intervention group
Group type: COMPARATOR
Intervention: Rice-based ORS (100 ml/kg)
Number of subjects: 150
Study 7743989 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding (absence)
Number of subjects: 150
Study 7743989 — intervention group
Group type: COMPARATOR
Intervention: Non-breast-fed children
Number of subjects: 150
Study 7743989 — intervention group
Group type: EXPERIMENTAL
Intervention: Low weight-for-height
Number of subjects: 150
Study 7743989 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or severe dehydration
Number of subjects: 150
Study 7743989 — intervention group
Group type: EXPERIMENTAL
Intervention: Low plasma specific gravity or total plasma protein
Number of subjects: 150